88% of Health Economics Teams Outside the US Rely on Patient Reported Outcomes

Patient-Reported Outcomes Increasingly Add Value to Reimbursement Discussions, Finds Cutting Edge Information

88% of Health Economics Teams Outside the US Rely on Patient Reported Outcomes

<0> Cutting Edge InformationElio Evangelista, 919-403-6583 </0>

The majority of pharma companies in the North America, Europe and the Asia-Pacific region use (PROs) to supplement outcomes data, according to a new study from Cutting Edge Information.

Cutting Edge Information’s recent study, “Health Economics and Outcomes Research: Aligning Clinical and Commercial to Meet Payer Demands and Win Reimbursement,” found a widespread prevalence of PRO usage among health economics teams. PRO usage is highest among companies in Europe, Canada and Australia, with 88% of surveyed companies relying on this data. Additionally, 75% of surveyed companies in emerging markets use PROs, as do 55% of surveyed US-based companies.

“For the majority of products, PROs offer a wealth of otherwise unknown data,” said Michelle Vitko, senior research analyst at Cutting Edge Information. “In the face of a shaky global economy and tightening budgets, payers are looking for more outcomes and scientific data to make decisions.”

To provide the required scientific data, many pharmaceutical and medical device companies have focused on PROs. By gathering data on quality of life, patient satisfaction, pain relief, absenteeism and more, PROs make the HEOR teams’ data more comprehensive and thereby increase the likelihood of reimbursement.

Of course, PRO data cannot stand alone; it must work in conjunction with other outcomes metrics. continue to rely on cost-utility data and other research models to demonstrate products’ benefits. Successful companies incorporate input from all stakeholders to best showcase a product’s effectiveness.

“Health Economics and Outcomes Research: Aligning Clinical and Commercial to Meet Payer Demands and Win Reimbursement,” is available at Cutting Edge Information’s website here: . This research explores HEOR teams across all company sizes, and in key geographic areas. This study is designed to help companies build effective health economics teams and improve their internal implementation, as well as communication with payers. This study helps companies:

For more information about health economics and outcomes research or , contact Elio Evangelista, 919-403-6583.

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.